Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 10, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and does not contain financial performance data for a specific fiscal period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of share transactions and does not include financial statements.
Material Changes
The filing details two specific transactions regarding share ownership:
- Employee Trust Transfer: On March 9, 2005, Abacus (GSK) Trustees Limited transferred 4,908 Ordinary Shares from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Director Share Acquisition: On March 9, 2005, Director Mr. J D Coombe acquired 20 Ordinary Shares (10 via personal contribution and 10 via company matching) under the ShareReward Plan at a price of £12.8255 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to reporting regulatory compliance regarding director shareholdings.
Investor Verification Checklist
- Verify the total number of shares held by the GSK Trust following the transfer of 4,908 shares.
- Confirm the updated shareholding balance for Director Mr. J D Coombe post-acquisition.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 and the ShareReward Plan to understand vesting conditions.
- Check the company's Form 20-F for comprehensive financial results, as this 6-K contains no financial metrics.